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Two novel coumarin-based ligands, coumarin-6,7-dioxyacetic acid (1) (cdoaH2) and 4-methylcoumarin-6,7-dioxyacetic acid (2) (4-
MecdoaH2), were reacted with copper(II) and manganese(II) salts to give [Cu(cdoa)(H2O)2] Æ 1.5H2O (3), [Cu(4-Mecdoa)(H2O)2] (4),
[Mn(cdoa)(H2O)2] (5) and [Mn(4-Mecdoa)(H2O)2] Æ 0.5H2O (6). The metal complexes, 3–6, were characterised by elemental analysis,
IR and UV–Vis spectroscopy, and magnetic susceptibility measurements and were assigned a polymeric structure. 1 and 2 react with
Cu(II) in the presence of excess 1,10-phenanthroline (phen) giving [Cu(cdoa)(phen)2] Æ 8.8H2O (7) and [Cu(4-Mecdoa)(phen)2] Æ 13H2O
(8), respectively. The X-ray crystal structures of 7 and 8 confirmed trigonal bipyramidal geometries, with the metals bonded to the four
nitrogen atoms of the two chelating phen molecules and to a single carboxylate oxygen of the dicarboxylate ligand. The complexes were
screened for their antimicrobial activity against a number of microbial species, including methicillin-resistant Staphylococcus aureus
(MRSA), Escherichia coli and Candida albicans. The metal-free ligands 1 and 2 were active against all of the microbes. Complexes 3–
6 demonstrated no significant activity whilst the phen adducts 7 and 8 were active against MRSA (MIC80 = 12.1 lM), E. coli
(MIC80 = 14.9 lM) and Patonea agglumerans (MIC80 = 12.6 lM). Complex 7 also demonstrated anti-Candida activity (MIC80 = 22 lM)
comparable to that of the commercially available antifungal agent ketoconazole (MIC80 = 25 lM).
 2007 Elsevier Inc. All rights reserved.
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The phenomenum of drug-resistance in microbial strains
emerged within a few years of penicillin being put on the
market when scientists began noticing the emergence of a
penicillin-resistant strain of Staphylococcus aureus, a com-
mon bacterium which causes a variety of suppurative
(pus-forming) infections and toxinoses in humans. From
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antimicrobial resistance has snowballed into a serious pub-
lic health concern with economic, social and political impli-
cations. Of particular concern has been the emergence of
methicillin-resistant S. aureus (MRSA) and recent reports
indicate that community-associated MRSA now has
reached epidemic proportions in many areas and has
become a worldwide problem [1–7].
Drug-resistance to antifungal agents is also of increasing
concern. Candida albicans is the major fungal pathogen in
humans and is carried by over 50% of the population.
Although in healthy individuals the pathogen may cause
relatively minor health problems, such as oral thrush, the
interactions of a fungus with its host can be disturbed by
hormonal or immunological imbalances in the host to the
point of provoking serious superficial infections and life-
threatening systemic infections [8–10]. The increasing prev-
alence of fungal infections, especially hospital-acquired
infections and infections in immunocompromised patients,
has heightened the need for new anti-fungal treatments
[11–14]. Drug-resistant fungal isolates have been reported
for all known cases of antifungal drugs [15–17]. Thus, there
is an urgent need to develop new and more effective anti-
fungal therapies.
In an earlier study by our group it was found that the
metal-based drugs [Cu(phen)2(mal)] Æ 2H2O, [Mn(phen)2-
(mal)] Æ 2H2O and [Ag2(phen)3(mal)] Æ 2H2O (phen = 1,10-
phenanthroline, malH2 = malonic acid) demonstrated a
different mode of action compared to the commonly used
commercial polyene and azole antifungal drugs [18]. It
was established that both metal-free phen and the metal–
phen complexes affect mitochondrial function, by retarding
the synthesis of cytochromes b and c and uncoupling cellu-
lar respiration. Treatment of fungal cells with the Cu(II)
and Ag(I) complexes resulted in a reduced amount of
ergosterol in the cell membrane and a subsequent increase
in its permeability. Cells exposed to metal-free phen and
the Cu(II) and Mn(II) complexes (but not the Ag(I) com-
plex) demonstrated an elevation in oxygen uptake.
Lately, a number of metal complexes of coumarins have
been synthesised and their biological activity determined.
Triorganotin(IV) derivatives of 7-hydroxycoumarin have
shown good antimicrobial activity against S. aureus and
Bacillus subtilis, C. albicans and Microsporum gypseum,
and this activity was slightly enhanced upon adduct forma-
tion with phen [19]. Kostova et al. have shown the cytotoxic
potential of coumarins complexed to cerium, lanthanum,
zirconium and neodymium ions [20–24]. Whilst our initial
work concentrated on the anticancer activity of a series of
substituted coumarins [25–31], more recently we have inves-
tigated the antimicrobial activity of a number of coumarin-
based Ag(I) and Cu(II) complexes [32,33], with the activity
of a number of complexes against C. albicans being compa-
rable to that of commercially used drugs such as ketocona-
zole. We have also reported an Ag(I) coumarin complex
which showed significant activity against the clinically
important bacterial strain MRSA (MIC80 = 0.63 lM) [33].In the present work, we have prepared coumarin-derived
dioxyacetic acid ligands and isolated their Cu(II) and
Mn(II) complexes as well as the phen adducts of the Cu(II)
complexes. The metal-free ligands, their metal complexes
and the simple salts, Mn(ClO4)2 Æ 6H2O and Cu(ClO4)2 Æ
6H2O were tested against clinical isolates of both Gram-
positive and Gram-negative bacteria and also against a
clinical isolate of C. albicans. The modes of action of
selected compounds, showing anti-Candida activity, were
also investigated.
2. Experimental
2.1. Materials/instrumentation
Reagent grade chemicals and solvents were purchased
from Sigma–Aldrich Co. (Dorset, UK) and were used
without further purification. Infrared spectra of solids (in
a KBr matrix) were recorded in the region 4000–
400 cm1 on a Nicolet Impact 410 Fourier-Transform
Infrared Spectrophotometer. Melting points were recorded
on a Stuart Scientific SMP-1 apparatus (up to 300 C). A
JEOL JNM-LA300 FT NMR spectrometer was used to
record 1H (300 MHz, 5 to 15 ppm from TMS) and 13C
(79 MHz, 33 to 233 ppm from TMS) NMR spectra of
the ligands as solutions in d6-DMSO. Atomic absorption
spectroscopy measurements were recorded on a Perkin–
Elmer 460 AAS instrument (emission wavelength 324.8
nm). Microanalytical data were provided by the Micro-
analytical Laboratory, National University of Ireland,
Belfield, Dublin 4. Solid state magnetic susceptibility
measurements were carried out at room temperature using
a Johnson Matthey Magnetic Susceptibility Balance
with [HgCo(SCN)4] being used as a reference standard.
UV–Vis spectra were recorded using a Cary IE Varian
UV–Vis spectrophotometer. Sterol concentrations were
determined using a gas chromatographic system (Hew-
lett–Packard 5890, Series 11) with a flame ionisation detec-
tor and a Chromopack capillary column (Chromopack
International BV, Middleburg, The Netherlands) operated
isothermally at 300 C. Injector and detector temperatures
were 320 C and the carrier gas was N2.
2.2. Ligand synthesis
Assignments of 1H NMR spectra of ligands are based
on the numbering scheme shown in Fig. 1.
2.2.1. Coumarin-6,7-dioxyacetic acid (2-(2-oxo-2H-
chromen-6-yloxy-7-carboxymethyloxy)acetic acid)
(cdoaH2)(1)
A suspension of 6,7-dihydroxycoumarin (2.00 g,
11.2 mmol) and potassium carbonate (3.41 g, 24.7 mmol)
in acetone (100 mls) was refluxed for 0.5 h. Upon cooling,
methyl bromoacetate (4.29 g, 2.7 ml, 28.1 mmol) was
added over a 5 min period and the resulting solution was
refluxed for a further 4 days. After cooling, the mixture
OO
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HO
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HO
O
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1. R = H,
2. R = Me
Fig. 1. Numbering scheme used for 1H NMR assignment of ligands used
in this study.
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off-white, crude solid. This solid was recystallised from
methanol to give the white solid dimethyl coumarin-6,7-
dioxyacetate. The purity of the product was confirmed by
TLC and 1H NMR analysis (Yield 2.2 g, 56%).
A mixture of dimethyl coumarin-6,7-dioxyacetate
(2.50 g, 7.75 mmol) in distilled water (50 ml) and concen-
trated hydrochloric acid (37%, 5 ml) was refluxed for
5 h. On cooling, the white solid cdoaH2 (1) precipitated.
The solid was filtered off, washed with cold ethanol and
water and then dried for 4 days in vacuo at 50 C. Yield:
2.2 g (96%); m.p. 218–220 C; TLC 0.14 [(70:30) ethyl ace-
tate:hexane]; Anal. Calc. for C13H10O8: C, 53.07; H, 3.42.
Found: C, 52.92; H, 3.34%. 1H NMR (d6-DMSO, ppm; s,
single; d, doublet): 4.72 (s, 2H, –OCH2COOH), 4.84 (s,
2H, –OCH2COOH), 6.27 (d, J = 9.3 Hz, 1H, vinyl-H3),
7.93 (d, J = 9.5 Hz, 1H, vinyl-H4), 6.98 (s, 1H, Ar-H5),
7.21 (s, 1H, Ar-H8); 13C NMR (d6-DMSO, ppm): 65.1,
65.4 (CH2–O), 101.4 (Ar C–H8), 111.4 (Q, Ar Cfused),
111.6 (Ar C–H5), 113.2 (C–Hvinyl), 144.2 (C–Hvinyl),
144.1 (Q, Ar Cfused–O), 149.4 (Q, Ar Cfused–O), 150.9 (Q,
Ar Cfused–O), 160.2 (Q, C@Olactone), 169.5, 169.9 (Q;
C@Oacid). IR (cm
1): mOH 3271, mC@O(acid) 1755,
mC@O(lactone) 1730. Soluble in: DMSO, alcohols, hot
water.2.2.2. 4-Methylcoumarin-6,7-dioxyacetic acid (2-2-oxo-2H-
chromen-4-methyl-6-yloxy-7-carboxymethyloxy)acetic acid,
(4-MecdoaH2) (2)
This white compound was synthesised by the same
method as that employed to prepare (1) except 4-methyl-
6,7-dihydroxycoumarin was used instead of 6,7-dihydroxy-
coumarin. Yield: 1.65 g (91%); m.p. 240–242 C; TLC 0.11
[(70:30) ethyl acetate:hexane]; Anal. Calc. for C14H12O8; C,
54.55; H, 3.92. Found: C, 54.29; H, 3.82%. 1H NMR (d6-
DMSO, ppm, s, singlet: d, doublet): 2.38 (d, J = 1.1 Hz,
3H, CH3), 4.82 (s, 2H, –OCH2COOH), 4.88 (s, 2H, –OCH2-
COOH), 6.23 (d, J = 1.1 Hz, 1H, vinyl-H3), 7.01 (s, 1H,
Ar-H5), 7.18 (s, 1H, Ar-H8); 13.11 (COOH); 13C NMR
(d6-DMSO, ppm): 18.3 (CH3), 65.1, 65.8 (CH2–O), 101.4
(Ar C–H8), 109.1 (Q, Ar Cfused), 112.4 (C–Hvinyl), 111.7
(Ar C–H5), 144.1 (Q, Ar Cfused–O), 148.8 (C–Hvinyl),151.0, 153.2 (Q, Ar C–O), 160.2 (Q, C@Olac) 169.5, 170.0
(Q, C@Oacid). IR (cm
1): mOH 3046, mC@O(acid) 1760,
mC@O(lactone) 1741. Soluble in: DMSO, alcohols, hot
water.
2.3. Syntheses of Cu(II) and Mn(II) complexes
2.3.1. [Cu(cdoa)(H2O)2] Æ 1.5H2O (3)
cdoaH2 (1) (0.200 g, 0.68 mmol) was dissolved in an eth-
anol:water mixture (4:1, 50 ml) with heating and stirring.
Dicopper(II) tetraacetate dihydrate (0.135 g, 0.340 mmol)
was added with stirring and the resulting solution was then
refluxed with stirring for 2 h. A pale blue precipitate
formed during reflux. The mixture was filtered whilst hot
and the blue solid was washed with water and hot ethanol
and then air-dried. Yield: 0.24 g (86%); Anal. Calc. for
C13H14CuO11: C, 37.28; H, 3.61; Cu, 15.17. Found: C,
37.42; H, 3.44; Cu, 14.95%. IR (cm1): mOH 3052, mC@O(lac-
tone) 1685, masym(OCO) 1607, msym(OCO) 1395, masym(COC)
1277, msym(COC) 1048, mM-O 819. leff: 1.98 B.M.; Soluble in:
DMSO. UV–Vis (DMSO): k291 nm e = 9770 M
1 cm1,
k340 nm e = 12,800 M
1 cm1, k741 nm e = 24.6 M
1 cm1:
UV–Vis (Nujol): k = 747 nm.2.3.2. [Cu(4-Mecdoa)(H2O)2] (4)
This blue complex was synthesised by the same method
as that employed for (3), using 4-MecdoaH2. Yield: 0.21 g
(79%); Anal. Calc. for C14H14CuO10: C, 41.44; H, 3.48; Cu,
15.60. Found: C, 41.26; H, 3.31; Cu, 15.45%. IR (cm1):
mOH 3309, mC@O(lactone) 1752, masym(OCO) 1605,
msym(OCO) 1397, masym(COC) 1279, msym(COC) 1049,
mM-O 844, 819. leff: 1.93 B.M.; Soluble in: DMSO. UV–
Vis (DMSO): k285 nm e = 13,100 M
1 cm1, k336 nm e =
17,200 M1 cm1, k796 nm e = 26.7 M
1 cm1: UV–Vis
(Nujol): k = 787 nm.
2.3.3. [Mn(cdoa)(H2O)2] (5)
This white compound was synthesised by the same
method as that employed for (3) using MnCl2 Æ 4H2O.
Yield: 0.110 g (25%); Anal. Calc. for C13H12MnO10; C,
40.74; H, 3.15. Found: C, 40.26; H, 3.01%. IR (cm1):
mOH 3421, mC@O(lactone) 1746, masym(OCO) 1616,
msym(OCO) 1395, masym(COC) 1280, msym(COC) 1037,
mM-O 832. leff: 5.88 B.M.; Soluble in: DMSO. UV–Vis
(DMSO): k273 nm e = 4575 M
1 cm1, k303 nm e = 4943
M1 cm1.2.3.4. [Mn(4-Mecdoa)(H2O)2] Æ 0.5H2O (6)
This white compound was synthesised by the same
method as that employed for (5), using 4-MecdoaH2.
Yield: 0.150 g (64%); Anal. Calc. for C14H15MnO10.5; C,
43.32; H, 3.38. Found: C, 43.27; H, 3.28%. IR (cm1):
3401, mC@O(lactone) 1727, masym(OCO) 1601, msym(OCO)
1392, masym(COC) 1275, msym(COC) 1048 cm
1; mM-O 820.
leff: 5.93 B.M.; Soluble in: DMSO. UV–Vis (DMSO):
k279 nm e = 3677 M
1 cm1, k380 nm e = 2687 M
1 cm1.
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A solution of cdoaH2 (0.200 g, 0.680 mmol), dicop-
per(II) tetraacetate dihydrate (0.135 g, 0.340 mmol) and
phen (0.247 g, 1.37 mmol) in an ethanol:water mixture
(4:1, 50 mls) was refluxed for 3 h and upon cooling a green
precipitate formed. The solid was isolated by filtration,
washed with water and ethanol and dried in a vacuum oven
at 50 C for 2 days. Yield: 0.311 g (52%); Anal. Calc. for
C37H36CuN4O14, C, 53.92; H, 4.40; N, 6.80. Found: C,
53.55; H, 4.35; N, 6.36%. IR (cm1): mOH 3036, mC@O(lac-
tone) 1707, masym(OCO) 1617, 1565, msym(OCO) 1395,
1426, masym(COC) 1277, msym(COC) 1037. leff: 1.86 B.M.
Soluble in: DMSO, alcohols, hot water. UV–Vis (DMSO):
k270 nm e = 68,300 M
1 cm1, k335 nm e = 13,300 M
1
cm1, k696 nm e = 77 M
1 cm1: UV–Vis (Nujol): k =
803 nm. Crystals suitable for X-ray diffraction studies
were obtained by redissolving the solid in a 1:1 metha-
nol:water mixture and allowing the solution to stand for
several days.2.3.6. [Cu(4-MeCdoa)(phen)2] Æ 7H2O (8)
This green compound was synthesised by the same
method as that employed for (7) using 4-MecdoaH2. Yield:
0.286 g (48%); Anal. Calc. for C38H40CuN4O15; C, 53.3; H,
4.71; N, 6.54. Found: C, 53.97; H, 4.54; N, 6.43%. IR
(cm1): mOH 3411, mC@O(lactone) 1712, masym(OCO) 1616,
1565, msym(OCO) 1391, 1426, masym(COC) 1277, msym(COC)Table 1
Crystal data and structure refinement for 7 and 8
Complex 7
Empirical formula C37H41.60CuN4O16.80
Formula weight 874.68
Temperature (K) 150(2)
Wavelength (A˚) 0.71073
Crystal system Triclinic
Space group P1
a (A˚) 10.9390(3)
b (A˚) 11.5730(3)
c (A˚) 15.9080(4)
Volume (A˚3) 1916.51(9)
Z 2
Density (calculated, Mg/m3) 1.516
Absorption coefficient (mm1) 0.653
F(000) 910
Crystal size (mm) 0.35 · 0.25 · 0.10
Theta range () 3.57–27.43
Index ranges 14 6 h 6 13; 14 6 k
Reflections collected 33,659
Independent reflections [Rint] 8615 [0.0695]
Reflections observed 6312
Data Completeness 0.987
Absorption correction Semi-empirical from equ
Maximum and minimum transmission 0.9544
Refinement method Full-matrix least-square
Data/restraints/parameters 8615/15/607
Goodness-of-fit on F2 1.081
Final R indices [I > 2r(I)] R1 = 0.0617 wR2 = 0.13
R indices (all data) R1 = 0.0942 wR2 = 0.15
Largest difference in peak and hole (eA˚3) 1.136 and 0.8161037. leff: 1.91 B.M.; Soluble in: DMSO, alcohols, hot
water. UV–Vis (DMSO): k290 nm e = 54,208 M
1 cm1,
k342 nm e = 14,776 M
1 cm1, k742 nm e = 67.2 M
1 cm1:
UV–Vis (Nujol): k = 820 nm. Crystals suitable for X-ray
diffraction studies were obtained by redissolving the solid
in a 1:1 methanol:water mixture and allowing the solution
to stand for several days.2.4. X-ray crystallography
Single crystals of 7 and 8 were analysed at 150 K using a
Nonius Kappa CCD diffractometer equipped with graphite
monochromated Mo Ka radiation. Details of the data col-
lections, solutions and refinements are given in Table 1.
Both structures were solved using SHELXS-97 [34] and
refined using full-matrix least-squares in SHELXL-97 [35].
Convergence was uneventful, with the following points of
note. The asymmetric unit of 7 consists of one copper com-
plex molecule and 8.8 water molecules. Hydrogens were
located for all full water molecules (O10, O11, O12, O13,
O14, O16) and for the partial water based on O15 (75%
occupancy). These solvent hydrogens were refined at a dis-
tance of 0.89 A˚ from the relevant parent atoms. The
remaining water hydrogen atoms could not be readily
located, even by considering a difference Fourier electron
density map computed on low Bragg angle data, and hence
they were omitted from the refinement. In addition to one8
C38H52CuN4O21
964.38
150(2)
0.71073
Triclinic
P1
11.0260(2)
13.4450(3)
16.0120(4)
2208.62(8)
2
1.450
0.580
1010
0.25 · 0.20 · 0.10
4.17–27.45
6 14; 19 6 l 6 20 14 6 h 6 14; 16 6 k 6 17; 20 6 l 6 20
41,143
10038 [0.0526]
7296
0.993
ivalents None
0.870
s on F2 Full-matrix least-squares on F2
10038/39/683
1.075
88 R1 = 0.0495 wR2 = 0.1249
35 R1 = 0.0783 wR2 = 0.1385
0.594 and 0.503
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was seen to also contain 13 full occupancy waters. The sol-
vent hydrogens were universally located and refined in a
similar manner to those in 7.
Crystallographic data for 7 and 8 have been deposited
with the Cambridge Crystallographic Data Centre as sup-
plementary publications CCDC 622270 and 622271,
respectively. Copies of the data can be obtained free of
charge on application to CCDC, 12 Union Road, Cam-
bridge CB2 1EZ, UK [fax(+44) 1223 336033, e-mail:
deposit@ccdc.cam.ac.uk].
2.5. Antimicrobial studies
2.5.1. Assessment of antibacterial activity
All bacterial isolates were obtained clinically: S. aureus
(urinary track infection), methicillin resistant S. aureus
(wound infection), Staphylococcus simulans (facial skin),
Micrococcus luteus (facial skin), Escherichia coli (gastro-
intestinal tract), Bacillus oleronius (facial skin), Patonea
agglumerans (facial skin).
Bacterial strains were grown overnight in nutrient broth
medium at 30 C and 200 rpm in an orbital incubator. The
absorbance of these cultures was measured at 660 nm and
cultures were diluted to an optical density of 0.1. The cell
suspension (100 ll) was added to the wells of a 96 well plate
containing test compound dissolved in nutrient broth med-
ium in serial dilutions from 100 to 0.25 lg/ml. Test com-
pounds for all the antimicrobial studies were initially
prepared in DMSO and then diluted with nutrient broth,
as above, so that the final concentration of DMSO in the cell
suspension was never more than 1%. Plates were incubated
at 30 C for 24 h and the optical density was measured spec-
trophotometrically (Dynex Technology) at 450 nm.
2.5.2. Antifungal susceptibility testing
C. albicans ATCC 10231 (obtained from the American
Type Culture Collection, MD, USA) was maintained on
YEPD agar [2% (w/v) glucose (Sigma–Aldrich Chemical
Co Ltd., Dublin, Ireland), 2% (w/v) bactopeptone (Difco
Laboratories, Detroit, USA), 1% (w/v) yeast extract (Oxoid
Ltd., Basingstoke, England), 2% (w/v) agar] plates and sub-
cultured every 6–8 weeks and stored at 4 C. Fresh cultures
were grown at 30 C in YEPD broth (as above but without
agar). All cultures were grown to the stationary phase
(approximately 1 · 108 cells/ml) overnight in 50 ml Antibi-
otic Medium 3 (Oxoid Ltd.) broth at 30 C and 200 rpm.
Antifungal susceptibility testing was performed using
broth microdilution assays according to the National Com-
mittee for Clinical Laboratory standards (Document M27-
A2) protocol with slight modifications. The M27-A2
method was altered by substituting antibiotic medium 3
for RPMI 1640 medium. Using this method MIC80 values
were determined spectrophotometrically at 405 nm by
comparing the turbidity of growth in each well. MIC80 is
defined as the lowest concentration of drug that inhibits
fungal growth by 80% relative to the control.2.5.3. Measurement of oxygen uptake
The respiration rate of yeast cells was determined using
a Clark-type oxygen electrode (Techne, Rank Brothers
Ltd., Cambridge, UK). This electrode consists of a plati-
num cathode and silver anode. Both the cathode and anode
were immersed in a potassium chloride buffer and are sep-
arated from the test solution by a Teflon membrane. A disc
of lens tissue with a hole in the middle was placed over the
anode and cathode, in order to leave the cathode uncov-
ered. The lens tissue had previously been immersed in
0.5 M potassium chloride. Following this, a Teflon mem-
brane was placed over the electrode and the test chamber
was placed on top of the electrode and screwed to place.
This chamber was maintained at 30 C by circulating water
around the walls of the chamber.
Prior to the determination of respiration rates, the elec-
trode was calibrated using sodium dithionate, thus allowing
determination of 100% and 0% oxygen levels. Yeast cells in
the late exponential phase (10 h), were grown in the presence
of test agent, using a concentration equivalent to half the
MIC80 at 30 C, and in an orbital incubator (Certomat R).
Yeast cells at a density of 1 · 108 cells were harvested
and washed in PBS and then resuspended in 0.025 M phos-
phate buffer, pH 7.2. Phosphate buffer (0.025 M) was pre-
pared following the addition of 72 ml of 0.05 M disodium
hydrogen phosphate, and 28 ml of 0.05 M sodium dihydro-
gen phosphate, to a final volume of 100 ml in distilled
water. Oxygen consumption was determined following
the addition of 100 ll of cell sample into the oxygen elec-
trode sample chamber, which previously contained 1.9 ml
of phosphate buffer. The rate of oxygen consumption was
measured for 30 s, with data recorded using a strip chart
recorder. Oxygen consumption was calculated using the
following formulae, and was expressed as lM of oxygen
consumed/108 cells. Oxygen consumption = number of
units travelled/span (100% level  0% level) · 468.75 lM.
2.5.4. Cytochrome analysis
Test agent was added to yeast cells and incubated for
10 h. Cells with a density of 2 · 1010 cells/ml were har-
vested by centrifugation at 3000g for 5 min, and washed
twice with PBS. The cells were divided into two equal vol-
umes, one half was oxidised by suspending in 0.2% (w/v)
sodium hypochlorite solution followed by harvesting using
centrifugation, and subsequently resuspended in 50% (v/v)
glycerol. The second half of the sample was resuspended in
50% (v/v) glycerol and reduced by adding a few crystals of
sodium-dithionate. Differential spectra of reduced and oxi-
dised cytochrome were immediately recorded using a dou-
ble beam UV–Vis spectrophotometer at 500–650 nm (Cary
IE Varian).
2.5.5. Sterol extraction
Yeast cells were grown in the presence of half the MIC80
concentration of test agent in antibiotic medium 3 at 30 C
in an orbital incubator (Certomat R), until cells reached
the late exponential phase (ca. 10 h). Cells at a density of
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were resuspended in 1.5 ml of a solution containing 20%
(w/v) potassium hydroxide and 60% (v/v) ethanol, and
placed in a shaking water bath at 90 C for 1.5–2 h. Hep-
tane was added to this solution and it was then vortexed
for 10 s. The upper layer containing sterols was removed
according to the method of Arthington-Skaggs et al. [36].
2.5.6. Analysis of yeast sterols
Sterol analysis was determined by using double beam
UV–Vis spectrophotometer (Cary IEVarian) over the wave-
length range of 240–320 nm. An ergosterol standard curve
was constructed (0.25–100 lg/ml). In addition, sterol con-
centration was also determined using a gas chromatograph.
3. Results and discussion
3.1. Chemical synthesis and characterisation
The dicarboxylate coumarin ligands 1 and 2 were pre-
pared by etherification of the precursor dihydroxycouma-
rins followed by acid hydrolysis (Scheme 1). The Cu(II)
and Mn(II) dicarboxylate complexes 3–6 were prepared
by simple ligand anion exchange reactions by refluxing
the appropriate dicarboxylate ligand with dicopper(II) tet-
raacetate dihydrate or manganese(II) chloride tetrahydrate
in water (Scheme 2). These dicarboxylate complexes were
insoluble in water and all common solvents (except
DMSO) suggesting they may be polymeric in nature, and
repeated attempts to recrystallise them failed. Elemental
analyses indicated a metal to ligand ratio of 1:1 and with
either two or three water molecules in the formulation.
The Cu(II) dicarboxylate/phen complexes 7 and 8 were
obtained by refluxing the respective coumarin-6,7-dioxy-
acetic acid with phen and dicopper(II) tetraacetate dihy-
drate in ethanol:water (4:1). These phen complexes were
soluble in hot water, alcohols and DMSO. The microana-
lytical data reported shows loss of water molecules from
the crystal lattice of both complexes over time. Attempts
to prepare the Mn(II) analogues were unsuccessful.
The IR masym(OCO) and msym(OCO) stretching frequen-
cies and the Dm(OCO) values for the metal complexes (3–
8) are listed in Table 2. The spectra of complexes 3–6 were
very similar and all had a Dm(OCO) > 200 cm1, a value-O
O
H3CO
H3CO
O
O
O
HO
OOH
R
Methyl bromoacetate
K2CO3, Acetone
Scheme 1. Synthesis of the coumarnormally considered to indicate unidentate carboxylate
coordination [37]. These data are also consistent with those
previously reported for Mn(II) and Cu(II) complexes of
benzene-1,2-dioxyacetic acid (bdoaH2) [38]. Ethereal
(COC) asymmetric and symmetric vibrational frequencies
for complexes 3–8 (Table 2) are also similar to those pub-
lished for benzene-1,2-dioxyacetate complexes [39–41]. The
X-ray structures of bdoa2 complexes indicated an octahe-
dral geometry about the metal centre, with the bdoa2
ligand coordinated in a quadridentate fashion via a carbox-
ylate oxygen from each of the acid functions and from the
two ethereal oxygen atoms [38]. However, while a similar
structure for complexes 3–6 could be possible, the general
insolubility of complexes 3–6 suggests that there may also
be intermolecular interactions between individual mono-
meric units (possibly via a carboxylate oxygen and/or the
lactone carbonyl oxygen) leading to polymeric structures.
Indeed, it is also possible that the quadridentate binding
environment about the metal centre could be generated
from carboxylate groups of alternating dioxyacetic acid
ligands. The IR spectra of the complexes 3–6 also contain
bands between 840 and 820 cm1, which are not present
in the free ligands, which are characteristic of coordinated
water [42]. The UV–Vis spectra of complexes 3 and 4,
recorded in DMSO solution as well as in the solid state
as a Nujol mull show approximately similar shapes and
positions of the absorption bands, indicating no apprecia-
ble change in the geometry of these complexes in solution.
The room temperature magnetic moment (leff) values of
complexes 3–6 (calculated by assuming a monomeric for-
mulation) are in agreement with those expected of simple
mononuclear complexes in which there are no metal–metal
interactions.
The IR spectra of the phen-containing complexes 7 and
8 were similar to each other and showed distinct bands for
the phen ligands at 1426, 850 and 723 cm1. For these two
complexes there were two separate sets of masym(OCO) and
msym(OCO) vibrations. One set of values, with Dm(OCO) >
200 cm1, was indicative of unidentate coordination to
the Cu(II) centre. Two additional bands at ca. 1426 and
1565 cm1, were assigned to masym(OCO) and msym(OCO)
vibrations of the uncoordinated carboxylate group [43].
The UV–Vis spectra of 7 and 8, recorded in DMSO
solution and as a Nujol mull do show appreciableO O
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Cu2(CH3COO)4·2H2O
Scheme 2. Synthesis of the coumarin-6,7-dioxyacetic acid complexes shown with proposed structures for complexes. Complexes 3–6 are likely to be
polymeric in nature.
Table 2
Selected IR data and magnetic moments for complexes 3–8
Compound masym(OCO) cm
1 msym(OCO) cm
1 DmOCO cm1 masym(COC) cm
1 msym(COC) cm
1 leff (B.M.)
[Cu(cdoa)(H2O)] Æ 1.5H2O (3) 1607 1395 212 1277 1048 1.98
[Cu(4-Mecdoa)(H2O)2] (4) 1605 1397 208 1279 1049 1.93
[Mn(cdoa)(H2O)2] (5) 1616 1395 221 1280 1037 5.88
[Mn(4-Mecdoa)(H2O)2)] Æ 0.5H2O (6) 1600 1392 208 1275 1048 5.94
[Cu(cdoa)(phen)2] Æ 8.8H2O (7) 1617 1390 227 1277 1037 1.86
1565 1426 139
[Cu(4-Mecdoa)(phen)2] Æ 13H2O (8) 1616 1391 225 1277 1037 1.91
1565 1426 139
1114 B.S. Creaven et al. / Journal of Inorganic Biochemistry 101 (2007) 1108–1119differences, indicating a change in stereochemistry about
the copper centre on dissolution [44].
3.2. Crystal structure analysis
The X-ray crystal structures of the Cu(II) complexes 7
and 8 are shown in Figs. 2 and 3, respectively, with perti-
nent bond lengths and angles listed in Tables 3 and 4,
respectively. The packing diagram for 7 is shown inFig. 4. There is extensive hydrogen bonding in both struc-
tures, involving available acceptors in the copper com-
plexes and the lattice waters.
Complex 7 has an approximate trigonal bipyramidal
geometry (s = 0.663) [45] with the metal coordinated by
two chelating phens and one oxygen (O1) of a carboxylate
function on the meridional trigonal plane (O1, N2, N4).
The acid group coordinated to the metal centre is the one
attached to the pendant ethereal arm 6-position of the
Fig. 2. Molecular structure of 7. Solvent and hydrogen atoms are omitted for clarity.
Fig. 3. Molecular structure of 8. Solvent and hydrogen atoms are omitted for clarity.
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to 2.123(3) A˚ and are similar to those reported for other
Cu–N bonds with N,N 0-donor ligands [46]. The copper to
oxygen bond length is 2.076(2) A˚ which is also similar to
other unidentate copper(II) carboxylate bond lengths
[47]. The bond angles of the meridian atoms illustrate
deviation from ideal trigonal bipyramidal geometry;
O1–Cu–N2, 102.54(10), N4–Cu–N2, 120.03(10) and
O1–Cu–N4, 137.39(10). The axial groups are close to per-
pendicular relative to the meridian plane, with N3–Cu–O1 = 90.56(10); N1–Cu–N4 = 95.72(11); N3–Cu–N1 =
177.19(11). There are also 8.8 water molecules per copper
centre. The second acid function of the diacid is uncoordi-
nated and deprotonated. The lactone oxygen of the couma-
rin, the ethereal oxygens of the dioxyacetic acid groups, the
deprotonated uncoordinated carboxylate group attached
to position 7 on the coumarin and the lattice waters are
involved in an extensive network of hydrogen bonding
(Fig. 4). Aryl stacking between the coordinated phen
groups affords added stability and rigidity in the solid state.
Table 3
Selected bond lengths (A˚) and angles () for [Cu(Cdoa)(phen)2] Æ 8.8H2O
(7)
Cu(1)–N(3) 1.984(3) Cu(1)–N(1) 1.988(3)
Cu(1)–O(1) 2.076(2) Cu(1)–N(4) 2.086(3)
Cu(1)–N(2) 2.123(3)
N(3)–Cu(1)–N(1) 177.19(11) N(3)–Cu(1)–O(1) 90.56(10)
N(1)–Cu(1)–O(1) 92.12(10) N(3)–Cu(1)–N(4) 81.72(11)
N(1)–Cu(1)–N(4) 95.72(11) O(1)–Cu(1)–N(4) 137.39(10)
N(3)–Cu(1)–N(2) 99.19(12) N(1)–Cu(1)–N(2) 81.06(12)
O(1)–Cu(1)–N(2) 102.54(10) N(4)–Cu(1)–N(2) 120.03(10)
Table 4
Selected bond lengths (A˚) and angles () for [Cu(4-Mec-
doa)(phen)2] Æ 13H2O (8)
Cu(1)–N(1) 1.995(2) Cu(1)–N(4) 2.004(2)
Cu(1)–O(1) 2.065(2) Cu(1)–N(2) 2.075(2)
Cu(1)–N(3) 2.144(2)
N(1)–Cu(1)–N(4) 176.06(10) N(1)–Cu(1)–O(1) 90.21(9)
N(4)–Cu(1)–O(1) 91.66(9) N(1)–Cu(1)–N(2) 81.45(9)
N(4)–Cu(1)–N(2) 99.39(9) O(1)–Cu(1)–N(2) 138.09(9)
N(1)–Cu(1)–N(3) 95.67(9) N(4)–Cu(1)–N(3) 80.53(9)
O(1)–Cu(1)–N(3) 102.97(8) N(2)–Cu(1)–N(3) 118.64(9)
Fig. 4. Packing diagram for [Cu
1116 B.S. Creaven et al. / Journal of Inorganic Biochemistry 101 (2007) 1108–1119The fused benzene rings of the coumarins may also be
engaged in aryl stacking. The structure of 7 is similar to
that reported for bis(2,2 0-bipyridine)p-(phenylenedi-
oxy)diacetatocopper(II) tetrahydrate [48].
The X-ray crystal structure of 8 (Fig. 3) is very similar to
7, with the Cu(II) center in a distorted trigonal bipyramidal
environment (s = 0.633) with two chelating phen ligands.
The 4-methylcoumarin-6,7-dioxyacetic in 8 acid has also
got one unidentate coordinated pendant carboxylate arm
(position-6) but unlike complex 7 it is coordinated through
the opposite oxygen of the carboxylate group.
3.3. Antibacterial screening
Manganese(II) and copper(II) dicarboxylates and their
phen adducts have previously been shown to have anti-
fungal activity against C. albicans [49–52]. The metal-free
ligands (1, 2), the metal complexes (3–8) and the simple
salts Cu(ClO4)2 Æ 6H2O and Mn(ClO4)2 Æ 6H2O were
screened for their antimicrobial activity (Table 5). The
growth inhibition results are expressed as MIC80 values
(minimum inhibitory concentration (lM) required to inhi-
bit 80% of the growth of the microbe).(cdoa)(phen)2] Æ 8.8H2O (7).
Table 5
Antimicrobial activity of test compounds [MIC80 (lM)]
Compound SA MRSA SS Ml E. Coli BO PA Can
1 282.5 194.9 267.2 84.2 153.3 240.2 167.3 87.74
2 264.4 208.1 293.6 92.6 149.5 159.6 153.7 98.5
3 >500 >500 >500 >500 >500 >500 >500 >500
4 >500 >500 >500 >500 >500 >500 >500 >500
5 >500 >500 >500 >500 >500 >500 >500 >500
6 >500 >500 >500 >500 >500 >500 >500 >500
7 19.9 12.1 17.8 22.8 14.9 31.9 12.6 22.2
8 24.3 37.5 28.3 43.7 44.7 27.5 74.1 42.7
Phen 259 150 223 315 >500 >500 448 16.7
Cu(ClO4)2 Æ 6H2O >500 >500 >500 >500 >500 >500 >500 >500
Mn(ClO4)2 Æ 6H2O >500 >500 >500 >500 >500 >500 >500 >500
(SA), Staphylococcus aureus: (MRSA), methicillin-resistant Staphylococcus aureus: (S. Sim) Staphylococcus simulans: (Ml) Micrococcus luteus: (E. Coli)
Escherichia coli: (BO) Bacillus olenius: (PA) Patonea agglumerans: (Can) Candida albicans.
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and 2 showed a similar and wide range of antibacterial
activity (MIC80 values ranging from 93 to 294 lM). How-
ever, the water-insoluble Cu(II) and Mn(II) dicarboxylate
complexes 3–6 and the water–soluble Cu(II) and Mn(II)
simple salts were inactive against all of the organisms.
These data indicate that decreasing the ligand solubility
(via complex formation) lowers the bioavailablility of the
dicarboxylates.
Complexes 7 and 8 had significantly greater antimicro-
bial activity than both the metal-free dicarboxylic acids
and phen, in particular against the clinically important
MRSA and E. coli bacteria (Table 5). Complexation with
phen or bipyridine has been used to enhance the antimicro-
bial activity of several metal ions, including copper [53–56].
Moreover, the phen ligand has been shown previously to
act as a potential anti-tumour agent [57] and that anti-
tumour activity can be increased on forming water-soluble
copper complexes [58]. In addition, copper complexes con-
taining phen are of considerable interest in nucleic acids
chemistry, following the discovery of the ‘chemical nucle-
ase’ activity of bis(phen)copper(I) complexes [59] and more
recently that of a copper(II) complex of a phen-derived
ligand [60]. A similar pattern is noted here in that the anti-
bacterial activity of metal-free phen is considerably
enhanced by the formation of Cu(II) complexes. Surpris-
ingly, 7 was universally more active than the methylated
analogue 8, implying that the methyl group in the 4-posi-
tion was having a deactivating effect. Overall, the activity
of 7, particularly against the clinically important MRSA
and P. agglumerans (MIC80 = 12.1 and 12.6 lM, respec-
tively), was considerably greater than the activity of phen,
the coumarin ligand or the copper salt suggesting that it
may well have therapeutic potential.0
Control 7 8
Fig. 5. Oxygen consumption of C. albicans. Fungal cells were treated with
the complexes 7 and 8 at half of their MIC80 concentrations for 10 h. Bars
indicate ±SEM. Control cells are those grown with no added complex.3.4. Antifungal activity
Against C. albicans metal-free phen and the phen-con-
taining Cu(II) complexes 7 and 8 had significantly lower
MIC80 values than the metal-free ligands 1 and 2 (Table 5).The values for 7 and 8were comparable to those of the com-
mercial antifungal agent ketoconazole (25 lM/ml) [33] but
interestingly were not as active as the metal-free phen. Thus,
unlike the antibacterial studies, whereby formation of a
Cu(II) phen complex enhances the antibacterial activity of
the phen ligand, the anti-Candida activity is reduced upon
complex formation. Given our previous mechanistic studies
on Cu(II)–phen complexes [18], some preliminary mode of
antifungal action studies on 7 and 8 were undertaken.
3.4.1. Respiration rates
Previous studies have shown that fungal respiration is
affected when cells are exposed to metal-based drugs
[18,61,62]. Stationary phase Candida cells were exposed
to 7 and 8 for 10 h and then oxygen-uptake measure-
ments were made (Fig. 5). The complexes show a modest
11118 B.S. Creaven et al. / Journal of Inorganic Biochemistry 101 (2007) 1108–1119reduction in O2 consumption, in comparison to the control.
An earlier study by our group has shown that metal-free
phen induces a modest increase in oxygen uptake [18].0
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Fig. 7. Ergosterol content of C. albicans. Fungal cells were treated with 7
and 8 at half of their MIC80 concentrations for 10 h. Bars indicate ±SEM.
Control cells are those grown with no added complex.3.4.2. Cytochrome analysis
Cytochromes are an important component of the mito-
chondrial electron transfer chain. Previous work has indi-
cated that impairment of cytochrome synthesis and/or
function leads to a reduction in respiration rates in Candida
cells following exposure to metal-based drugs [18,63]. The
spectroscopic cytochrome profile of control cells indicates
the presence of cytochromes aa3 (602 nm), b (564 nm)
and c (550–554 nm) (Fig. 6). However, their spectroscopic
profiles were altered when cells were exposed to 7 and 8.
In particular, the cytochrome aa3 peak was greatly reduced
in yeast cells treated with 8. Disruption of the mitochon-
drial cytochrome content of a cell has the potential to
reduce its respiratory efficacy. Again a previous study
had shown that metal-free phen retards the synthesis of
cytochromes b and c [18].
3.4.3. Ergosterol content
Fungal cells require oxygen in order to synthesise the
membrane sterol ergosterol. Thus, either a reduction in
respiratory efficiency or an inability to respire leads to
reduced levels of ergosterol [63]. Reduction in the ergosterol
content in C. albicans has been identified previously as a
mechanism for increased growth in the presence of the
potent anti-fungal drug amphotericin B [63,64]. The
requirement for a functional mitochondrion in ergosterol
biosynthesis is well established and arises from the provi-
sion of NADPH for squalene dimerisation [63]. The relative
ergosterol contents of drug-treated and control cells were
determined (Fig. 7). C. albicans cells exposed to complexes
7 and 8 showed diminished levels of ergosterol, with com-Fig. 6. Cytochrome profile of C. albicans. Fungal cells were treated with
the metal complexes 7 (B) and 8 (C) at half of their MIC80 concentrations
for 10 h. Control cells are those grown with no added complex (A).plex 7 inflicting the most deleterious effect. As sterol synthe-
sis is dependent upon a fully functional cellular respiratory
system the decrease in ergosterol levels observed with these
drugs indicate a disabled mitochondria.4. Conclusions
Two new coumarin-6,7-dioxyacetic acid ligands were
prepared and each complexed to a Mn(II) and Cu(II) cen-
tre. Mixed-ligand dicarboxylate/phen complexs of Cu(II)
were also isolated. The most active complexes, [Cu(cdoa)
(phen)2] Æ 8.8H2O (7) and [Cu(4-Mecdoa)(phen)2] Æ 13H2O
(8) displayed significant broad spectrum antimicrobial
activity with particularly good activity against MRSA,
E. coli and P. agglumerans.
It has previously been shown that N-donor derivatives
of the dicarboxylate complexes of a range of metals are
more effective antifungal agents than the simple dicarboxy-
late complexes and possess significantly different modes of
action to the state-of-the-art prescription drugs [53,60,18]
and the results presented here show a similar trend. When
administered to C. albicans 7 and 8 inhibited respiration,
reduced the levels of ergosterol in the membrane and
altered cytochrome content. These results suggest that the
antifungal effect of these complexes is mediated through
the disruption of mitochondrial function, which is different
to the mode of action of the conventional azole and poly-
ene drugs.
In light of their antimicrobial activities and their distinct
antifungal mode of action, 7 and 8 may find application as
novel drugs for the treatment of microbial infections, and
they may also be employed in conjunction with existing
drugs for the treatment of infections demonstrating resis-
tance to conventional agents.
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